Literature DB >> 9387201

Acquired von Willebrand disease in patients with high platelet counts.

U Budde1, P J van Genderen.   

Abstract

For patients with high platelet counts an inverse relationship has been established between platelet counts and large vWf multimers in plasma. Platelets are currently thought to be primarily involved in the pathogenesis of this decrease in plasma large vWf multimers, presumably by binding large vWf multimers, resulting in their effective removal from the circulation and/or by degrading (platelet-bound) vWf. In patients with myeloproliferative disorders associated with high platelet counts, a decrease in large vWf multimers in plasma may potentially compromise primary hemostasis. Patients with reactive thrombocytosis exhibit a similar reduction in large vWf multimers in plasma, but their clinical course is usually not complicated by bleeding, probably as a consequence of increased circulating vWf levels due to the behavior of vWf as a reactive protein, which compensates for the relatively decreased levels of large vWf multimers in plasma.

Entities:  

Mesh:

Year:  1997        PMID: 9387201     DOI: 10.1055/s-2007-996119

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  12 in total

Review 1.  Antiplatelet therapy in the management of myeloproliferative neoplasms.

Authors:  Alberto Alvarez-Larrán; Carlos Besses
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 3.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

Review 4.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

5.  Spontaneous hemopericardium leading to cardiac tamponade in a patient with essential thrombocythemia.

Authors:  Anand Deshmukh; Shanmuga P Subbiah; Sakshi Malhotra; Pooja Deshmukh; Suman Pasupuleti; Syed Mohiuddin
Journal:  Cardiol Res Pract       Date:  2011-01-18       Impact factor: 1.866

6.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

Review 7.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

8.  Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.

Authors:  Elizabeth M Kander; Sania Raza; Zheng Zhou; Juehua Gao; Anaadriana Zakarija; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

Review 9.  The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

10.  Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Authors:  Anna L Godfrey; Peter J Campbell; Cathy MacLean; Georgina Buck; Julia Cook; Julie Temple; Bridget S Wilkins; Keith Wheatley; Jyoti Nangalia; Jacob Grinfeld; Mary Frances McMullin; Cecily Forsyth; Jean-Jacques Kiladjian; Anthony R Green; Claire N Harrison
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.